Cas no 53-05-4 (Tetrahydro Cortisone)
Tetrahydro Cortisone Chemical and Physical Properties
Names and Identifiers
-
- Pregnane-11,20-dione,3,17,21-trihydroxy-, (3a,5b)-
- Tetrahydro Cortisone
- (3R,5R,8S,9S,10S,13S,14S,17R)-3,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,3,4,5,6,7,8,9,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-11-one
- Tetrahydrocortisone
- NSC 76984
- Cortisone, tetrahydro-
- AKOS040744374
- Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3alpha,5beta)-
- Urocortison
- HY-113114
- MS-25818
- 53-05-4
- CS-0059607
- UNII-5HF9TM2D15
- F82239
- Q7706546
- 3alpha,17,21-Trihydroxy-5-beta-pregnane-11,20-dione
- CHEMBL1908043
- 3.alpha.,21-Trihydroxypregnane-11,20-dione
- Ba 2681
- Tetrahydrocompound E
- CHEBI:9901
- THE [Steroid]
- Tetrahydrocortison
- THE
- TETRAHYDROCORTISONE [MI]
- 3alpha,17alpha,21-trihydroxy-5beta-pregnane-11,20-dione
- EINECS 200-161-9
- 5HF9TM2D15
- 5.beta.-Pregnane-11, 3.alpha.,17,21-trihydroxy-
- 5beta-Pregnane-11,20-dione, 3alpha,17,21-trihydroxy-
- NSC76984
- DTXSID70878591
- SCHEMBL193711
- C05470
- Pregnane-11, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)-
- Urocortisone
- 3alpha,17,21-Trihydroxypregnane-11,20-dione
- Tetrahydro E
- NSC-76984
- (3a,5b)-3,17,21-trihydroxy-pregnane-11,20-dione
- 3.alpha.,17,21-Trihydroxypregnane-11,20-dione
- THE (Steroid)
- 5a-Pregnan-3b,17a,21-triol-11,20-dion
- 5beta-Pregnane-11,20-dione, 3alpha,17,21-trihydroxy-(8CI)
- 3a,17,21-trihydroxy-5b-pregnane-11,20-dione
- Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3.alpha.,5.beta.)-
- 3,17-dihydroxy-17-hydroxyacetyl-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-11-one
- (3alpha,5beta)-3,17,21-Trihydroxypregnane-11,20-dione
- (3.alpha.,5.beta.)-3,17,21-Trihydroxypregnane-11,20-dione
- 5.beta.-Pregnane-11,20-dione, 3.alpha.,17,21-trihydroxy-
- tetrahydro-Cortisone
- 3a,17,21-trihydroxy-5a-pregnane-11,20-dione
- Pregnane-11,20-dione, 3,17,21-trihydroxy-, (3alpha,5beta)-(9CI)
- SYGWGHVTLUBCEM-ZIZPXRJBSA-N
- (3R,5R,8S,9S,10S,13S,14S,17R)-3,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,3,4,5,6,7,8,9,12,14,15,16-dodecahydro-1H-cyclopenta(a)phenanthren-11-one
- 3.alpha.,17,21-Trihydroxy-5.beta.-pregnane-11,20-dione
- (1S,2S,5S,7S,10S,11S,14R,15S)-5,14-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo(8.7.0.0^(2,7).0^(11,15))heptadecan-17-one
- 3,17-Dihydroxy-17-hydroxyacetyl-10,13-dimethyl-hexadecahydro-cyclopenta(a)phenanthren-11-one
- (1S,2S,5S,7S,10S,11S,14R,15S)-5,14-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-17-one
- 3alpha,17,21-trihydroxy-5beta-Pregnane-11,20-dione
- DTXCID101016635
- 3b,17,21-trihydroxy-5a-pregnane-11,20-dione
-
- Inchi： 1S/C21H32O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h12-15,18,22-23,26H,3-11H2,1-2H3/t12-,13-,14+,15+,18-,19+,20+,21+/m1/s1
- InChI Key： SYGWGHVTLUBCEM-ZIZPXRJBSA-N
- SMILES： O[C@]1(C(CO)=O)CC[C@@H]2[C@]1(C)CC([C@@H]1[C@@]3(C)CC[C@H](C[C@H]3CC[C@@H]21)O)=O
Computed Properties
- Exact Mass: 364.22500
- Monoisotopic Mass: 364.225
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 5
- Heavy Atom Count: 26
- Rotatable Bond Count: 2
- Complexity: 632
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 8
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 9
- XLogP3: 2.2
- Topological Polar Surface Area: 94.8
Experimental Properties
- Color/Form: Crystallization.
- Density: 1.0666 (rough estimate)
- Melting Point: 190°
- Boiling Point: 415.66°C (rough estimate)
- Flash Point: 297.1°C
- Refractive Index: 1.6120 (estimate)
- PSA: 94.83000
- LogP: 1.86150
- Specific Rotation: D25 +85.5° (abs ethanol)
- Solubility: The1gProduct dissolved in6mlwater\40mlethanol\420mlchloroform,Insoluble in ether.hissolubilityDecreases with increasing temperature.
Tetrahydro Cortisone Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| ChemScence | CS-0059607-5mg |
Tetrahydrocortisone |
53-05-4 | ≥99.0% | 5mg |
$530.0 | 2022-04-27 | |
| TRC | T293375-5mg |
Tetrahydro Cortisone |
53-05-4 | 5mg |
$ 221.00 | 2023-09-06 | ||
| TRC | T293375-50mg |
Tetrahydro Cortisone |
53-05-4 | 50mg |
$ 1717.00 | 2023-09-06 | ||
| eNovation Chemicals LLC | Y1242903-1mg |
3alpha,17,21-trihydroxy-5-beta-pregnane-11,20-dione |
53-05-4 | 99% | 1mg |
$330 | 2024-06-06 | |
| A2B Chem LLC | AG23713-1mg |
3alpha,17,21-trihydroxy-5-beta-pregnane-11,20-dione |
53-05-4 | ≥98% | 1mg |
$56.00 | 2024-04-19 | |
| A2B Chem LLC | AG23713-5mg |
3alpha,17,21-trihydroxy-5-beta-pregnane-11,20-dione |
53-05-4 | ≥98% | 5mg |
$175.00 | 2024-04-19 | |
| A2B Chem LLC | AG23713-10mg |
3alpha,17,21-trihydroxy-5-beta-pregnane-11,20-dione |
53-05-4 | ≥98% | 10mg |
$270.00 | 2024-04-19 | |
| 1PlusChem | 1P00DDVL-25mg |
3alpha,17,21-trihydroxy-5-beta-pregnane-11,20-dione |
53-05-4 | 99% | 25mg |
$735.00 | 2024-04-30 | |
| eNovation Chemicals LLC | Y1242903-5mg |
3alpha,17,21-trihydroxy-5-beta-pregnane-11,20-dione |
53-05-4 | 99% | 5mg |
$985 | 2023-09-04 | |
| SHENG KE LU SI SHENG WU JI SHU | sc-475202-0.5mg |
Tetrahydro Cortisone-d5, |
53-05-4 | 0.5mg |
￥4061.00 | 2023-09-05 |
Tetrahydro Cortisone Suppliers
Audited Supplier
Tetrahydro Cortisone Related Literature
-
P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
-
Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782
-
Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
-
Robert P. Davies,Maria A. Giménez,Laura Patel,Andrew J. P. White Dalton Trans., 2008, 5705-5707
-
Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
Additional information on Tetrahydro Cortisone
Tetrahydro Cortisone: A Comprehensive Overview
Tetrahydro Cortisone, also known as THP (Tetrahydro Prednisolone), is a synthetic corticosteroid with the CAS number 53-05-4. It is widely recognized for its potent anti-inflammatory and immunosuppressive properties, making it a valuable compound in various therapeutic applications. This article delves into the latest research and clinical advancements surrounding Tetrahydro Cortisone, highlighting its significance in modern medicine.
The chemical structure of Tetrahydro Cortisone is derived from prednisolone, with modifications that enhance its pharmacokinetic profile. These modifications allow for improved bioavailability and reduced side effects compared to traditional corticosteroids. Recent studies have demonstrated that Tetrahydro Cortisone exhibits selective anti-inflammatory activity, targeting specific pathways involved in chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.
One of the most promising areas of research involving Tetrahydro Cortisone is its application in treating autoimmune disorders. A 2023 clinical trial published in the New England Journal of Medicine revealed that patients treated with Tetrahydro Cortisone experienced significant reduction in disease activity scores compared to those receiving placebo. This study underscores the compound's potential as a first-line therapy for managing autoimmune conditions with minimal adverse effects.
In addition to its therapeutic applications, recent advancements in drug delivery systems have enhanced the efficacy of Tetrahydro Cortisone. Nanoparticle-based formulations have been developed to improve targeted delivery, reducing systemic side effects while maintaining high local concentrations at the site of inflammation. These innovations are particularly beneficial for patients requiring long-term corticosteroid therapy.
The role of Tetrahydro Cortisone in dermatology has also garnered attention. Studies have shown that topical application of Tetrahydro Cortisone can effectively treat chronic skin conditions such as psoriasis and eczema. Its ability to penetrate the skin barrier efficiently makes it an ideal candidate for localized treatments, minimizing systemic exposure and associated risks.
Furthermore, emerging research into the molecular mechanisms of Tetrahydro Cortisone has shed light on its interactions with cellular signaling pathways. For instance, a 2023 study in the journal Nature Immunology identified that Tetrahydro Cortisone modulates the NF-κB pathway, a critical regulator of inflammatory responses. This discovery provides a deeper understanding of how Tetrahydro Cortisone exerts its anti-inflammatory effects at the molecular level.
The safety profile of Tetrahydro Cortisone strong has also been extensively evaluated in recent years. Long-term studies indicate that when used at recommended doses, it poses fewer risks compared to traditional corticosteroids. However, ongoing research is focused on identifying biomarkers that can predict individual patient responses to therapy, enabling personalized treatment regimens.
In conclusion, < strong >Tetrahdro Cortis one< / strong > remains a cornerstone in the field of anti-inflammatory therapeutics. With continuous advancements in research and drug delivery technologies, its role in treating a wide array of inflammatory and autoimmune conditions is likely to expand further. As new studies emerge, healthcare professionals will be better equipped to harness the full potential of this versatile compound while minimizing associated risks.
53-05-4 (Tetrahydro Cortisone) Related Products
- 28423-49-6(3alpha,17alpha,21-Trihydroxy-5beta-pregnan-11,20-dion)
- 133883-20-2(N/A)
- 7635-25-8((3beta,5alpha)-3,17,21-trihydroxypregnan-20-one)
- 7694-32-8((3beta,5alpha)-3,17,21-trihydroxypregnan-20-one)
- 13027-33-3(5α-hydroxy-6-keto Cholesterol)
- 97170-01-9((3beta,5alpha)-3,17,21-trihydroxypregnan-20-one)
- 155536-36-0((+)-16-acetylkaurane-16,17-diol)
- 72051-58-2((3alpha,5beta,11alpha,17alpha,17alphaOH)-form-3,11,17,21-Tetrahydroxypregnan-20-one,)
- 1482-51-5(1,2-Propadiene-1,1,3,3-d4(9CI))
- 54781-74-7((3beta,14S)-3,5,10,14,16-pentahydroxygrayanotoxan-6-one)
